Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessment by EPISPOT of Circulating Tumor Cells as an Early Predictive Marker of Response to Chemotherapy and Targeted Therapy in Patients With Metastatic Colorectal Cancer in First Line of Treatment

NCT01596790 is registered in ClinicalTrials.gov with University Hospital, Montpellier as lead sponsor.

NCT NCT01596790
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01596790 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessment by EPISPOT of Circulating Tumor Cells as an Early Predictive Marker of Response to Chemotherapy and Targeted Therapy in Patients With Metastatic Colorectal Cancer in First Line of Treatment
Lead sponsor
University Hospital, Montpellier
Phase
Not applicable
Overall status
Completed
Start date
April 30, 2012
Completion date
September 30, 2019
Enrollment
168 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer